What Is ApoB?
Cardiovascular disease is the leading cause of death in the United States — for both men and women. And yet the test that most people receive to assess their cardiovascular risk, the standard lipid panel, misses some of the most important information available.
Not because the test is wrong. Because it's incomplete.
Most people leave their annual physical knowing their LDL cholesterol, their HDL cholesterol, and their total cholesterol. Most have no idea what their ApoB is. And ApoB is a more direct, more accurate predictor of cardiovascular events than any of those numbers.
This post is about what ApoB is, why it matters, and what a complete cardiovascular evaluation actually looks like — because heart disease is not something that announces itself until it's already advanced. The opportunity to change trajectory exists years before that happens, but only if someone is looking for the right things.
The Problem with LDL Alone
LDL — low-density lipoprotein — is a particle that carries cholesterol through the bloodstream. The conventional wisdom for decades has been that high LDL means high cardiovascular risk. And that relationship is real — but it's not the whole story.
Here's the issue. LDL is measured in most standard lipid panels as a concentration of cholesterol — how much cholesterol is being carried by LDL particles. What it doesn't tell you is how many LDL particles are carrying that cholesterol.
Two people can have identical LDL cholesterol levels of 120 mg/dL. One of them might have that cholesterol distributed among a relatively small number of large, buoyant LDL particles. The other might have the same amount of cholesterol spread across a much larger number of small, dense LDL particles. The second person has dramatically higher cardiovascular risk — because it's the number of particles passing through arterial walls that drives plaque formation, not simply the amount of cholesterol being carried.
LDL cholesterol doesn't capture this distinction. ApoB does.
What ApoB Actually Measures
Apolipoprotein B — ApoB — is a protein found on the surface of every atherogenic lipoprotein particle in the bloodstream. That includes LDL, VLDL, IDL, and Lp(a). Every one of these particles carries exactly one ApoB molecule. Which means ApoB is a direct count of the total number of atherogenic particles circulating in your blood.
This matters because particle number, not cholesterol concentration, is what drives atherosclerosis. Plaque builds when LDL particles penetrate the arterial wall and become oxidized. More particles means more penetration events, more oxidation, and more plaque formation over time — regardless of how much cholesterol each particle is carrying.
The research on this is consistent and substantial. Multiple large studies have shown that ApoB is a stronger predictor of major adverse cardiovascular events than LDL cholesterol — and that discordance between LDL and ApoB (meaning one is high while the other is normal) is common. When they disagree, ApoB is the more accurate risk indicator.
A patient with a normal LDL and an elevated ApoB is at higher cardiovascular risk than their cholesterol number suggests. That patient is being falsely reassured by an incomplete test.
Lp(a) — The Other Number Almost Nobody Checks
Lipoprotein(a) — Lp(a) — is a distinct lipoprotein particle that carries its own specific and significant cardiovascular risk, independent of LDL, ApoB, and every other conventional marker.
Lp(a) is largely genetically determined. Unlike LDL, it doesn't respond meaningfully to diet or lifestyle modification. It is elevated in approximately 20 percent of the population, and those individuals have a substantially higher lifetime risk of cardiovascular disease, aortic stenosis, and stroke — often without knowing it, because Lp(a) is almost never included in a standard lipid panel.
Normal Lp(a) is below 30 mg/dL. Borderline risk falls between 14 and 30 mg/dL. High risk is 31 to 50 mg/dL. Above 50 mg/dL represents the highest risk category — and some researchers prefer measuring in nanomoles per liter, where the high-risk threshold is above 100 nmol/L.
There is currently no approved medication specifically for elevated Lp(a), though several are in late-stage clinical trials. What elevated Lp(a) does change is how aggressively other cardiovascular risk factors should be managed — it is a signal to take LDL targets more seriously, to optimize every modifiable risk factor, and to consider additional monitoring including coronary artery calcium scoring.
Every patient at NOVA who undergoes a comprehensive cardiovascular evaluation gets Lp(a) measured. It's on our Functional Health Plus panel and our Advanced Cardiac Panel. Most patients have never had it checked before — and for the 20 percent who carry elevated levels, knowing is the difference between passive risk and active management.
The Inflammation Piece — hs-CRP
ApoB and Lp(a) address the particle question. But cardiovascular risk is not purely a particle problem. Inflammation is an independent driver of atherosclerosis — and the marker that captures it most sensitively in a clinical setting is hs-CRP, high-sensitivity C-reactive protein.
Elevated hs-CRP — above 2 mg/L — indicates chronic low-grade systemic inflammation that directly accelerates plaque formation and destabilization. A patient with a normal LDL, normal ApoB, and elevated hs-CRP is at meaningfully higher cardiovascular risk than their lipid panel suggests. The combination of metabolic dysfunction — insulin resistance, elevated triglycerides, low HDL — with elevated hs-CRP is one of the most common patterns I see in patients who haven't had a cardiac event yet but are moving toward one.
The good news is that hs-CRP responds to intervention. Resistance training, sleep optimization, dietary modification, omega-3 fatty acids, and addressing insulin resistance all have documented effects on inflammatory markers. The test gives you something to track and something to improve.
Why Women Need to Pay Particular Attention
Cardiovascular disease is the leading cause of death in women — a fact that most women don't know, because heart disease has been culturally framed as a male problem. It isn't.
Women develop cardiovascular disease several years later than men on average, but they are not protected from it — they are delayed from it. And the menopause transition is a time of accelerating cardiovascular risk. Estrogen has protective effects on the vascular endothelium and on lipid metabolism that begin to diminish during perimenopause. LDL rises. HDL's protective function becomes less reliable. Triglycerides increase. Systolic blood pressure begins to climb.
Women also carry sex-specific cardiovascular risk factors that standard risk calculators don't account for: history of gestational hypertension or gestational diabetes, polycystic ovary syndrome, early menopause, and autoimmune disease. A woman with a history of preeclampsia, for example, carries significantly higher lifetime cardiovascular risk — and that history is rarely captured in a conventional cardiovascular assessment.
This is one of the reasons I take cardiovascular evaluation seriously as part of hormone care, not separate from it. The timing of hormone therapy relative to the menopause transition has cardiovascular implications. The metabolic changes that accompany perimenopause are cardiovascular risk factors. And the women most in need of proactive cardiovascular assessment are often the ones who feel too young to worry about it.
What a Complete Cardiovascular Evaluation Looks Like at NOVA
For patients with cardiovascular risk factors, family history of heart disease, or who want a comprehensive longevity-focused evaluation, our Advanced Cardiac Panel provides a full picture: small dense LDL, ApoB, Lp(a), Lp-PLA2, hs-CRP, homocysteine, fasting insulin, CoQ10, and Vitamin D.
For patients in our Executive membership tier, coronary CT angiography with plaque characterization and coronary artery calcium scoring are included as part of the annual diagnostic package — imaging that tells us not just about risk factors but about the actual state of the coronary arteries.
For patients not in those categories, ApoB, Lp(a), and hs-CRP can be added individually to any panel. They're inexpensive tests. They take the same blood draw. And for the patients whose results change the picture, knowing is the most valuable thing we can offer them.
Cardiovascular disease doesn't begin at the heart attack. It begins decades earlier, in a process that is measurable, modifiable, and preventable when someone is paying attention. That's exactly the kind of attention we're here to provide.
Book a free 30-minute consultation at novawellnessut.com or call and text us at (801) 449-1402. We draw labs right here in the office — no separate lab visit required.
Matt Nelson, NP
NOVA Wellness — Orem, Utah
(801) 449-1402 · novawellnessut.com
